Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The MYC oncogene is frequently upregulated in human cancers through various genetic alterations.
• MYC/MAX heterodimers regulate gene transcription by binding to E box sequences.
• Omomyc is a known inhibitor of MYC transcriptional activity.

Purpose of the Study:

• To elucidate the precise molecular mechanism by which Omomyc inhibits MYC-mediated transcription.
• To investigate the binding preferences of Omomyc within the MYC/MAX complex.
• To explore the cotranslational formation of MYC-related heterodimers.

Main Methods:

• Chromatin immunoprecipitation (CHIP) was used to assess MYC/Omomyc binding.
• Proximity ligation assay (PLA) and double chromatin immunoprecipitation (ReCHIP) were employed to confirm binding interactions.
• Analysis of cotranslational heterodimer formation involving Myc, Max, and Omomyc.

Main Results:

• Omomyc preferentially binds to Max, not Myc, forming Omomyc/MAX heterodimers.
• These Omomyc/MAX heterodimers replace MYC/MAX heterodimers, inhibiting MYC-driven transcription.
• Heterodimer formation occurs cotranslationally, with Omomyc, Myc, and Max interacting with ribosomes and Max RNA.
• Omomyc exhibits rapid distribution to kidneys and liver with a short plasma half-life in vivo.

Conclusions:

• Omomyc inhibits the MYC oncogene by forming Omomyc/MAX heterodimers cotranslationally, representing a novel inhibitory mechanism.
• The binding of Omomyc to Max, rather than Myc, is key to its inhibitory function.
• The pharmacokinetic profile of Omomyc, including rapid distribution and short half-life, may limit its in vivo therapeutic application.